Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$1.13
-0.9%
$1.25
$0.87
$2.55
$21.50M0.43224,021 shs188,433 shs
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
$12.50
-2.0%
$13.24
$1.27
$15.85
$20.08M1.212,104 shs329 shs
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
$0.94
-0.5%
$0.94
$0.03
$1.03
$5.59M0.542,709 shs2,402 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.41
-0.6%
$3.35
$2.57
$6.88
$21.19M0.629,079 shs2,793 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-0.87%-2.56%-7.32%+1.79%+1.79%
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-1.96%-3.85%-8.09%-3.85%+691.14%
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.00%0.00%0.00%0.00%+1.63%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+0.29%+0.15%-0.87%+27.51%-39.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2.8016 of 5 stars
3.53.00.00.02.71.70.6
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.774 of 5 stars
0.05.00.00.00.01.70.6
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.4826 of 5 stars
0.04.00.00.03.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
3.00
Buy$8.50652.21% Upside
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
0.00
N/AN/AN/A
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
0.00
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest FRTX, CMMB, FNCH, and NAII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/A$14.25 per shareN/A
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
$10.06M0.56N/AN/A$1.66 per share0.56
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$13.94M-$0.76N/AN/AN/AN/A-106.70%-82.18%8/20/2025 (Estimated)
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
-$74.75M-$8.82N/AN/AN/A-69.14%-26.92%N/A
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
-$5.69M-$1.41N/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/25/2025 (Estimated)

Latest FRTX, CMMB, FNCH, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$0.20-$0.14+$0.06-$0.14N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/AN/AN/AN/AN/A
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/A
5.33
5.33
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
N/A
3.87
3.87
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
CompanyEmployeesShares OutstandingFree FloatOptionable
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2018.86 million16.61 millionNot Optionable
Finch Therapeutics Group, Inc. stock logo
FNCH
Finch Therapeutics Group
1901.61 million885,000No Data
Fresh Tracks Therapeutics, Inc. stock logo
FRTX
Fresh Tracks Therapeutics
205.97 million5.96 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable

Recent News About These Companies

Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results
CarnoSyn Brands announces new U.S. distribution pact with B&D Nutritional
(NAII) Trading Advice

New MarketBeat Followers Over Time

Media Sentiment Over Time

Chemomab Therapeutics stock logo

Chemomab Therapeutics NASDAQ:CMMB

$1.13 -0.01 (-0.88%)
Closing price 04:00 PM Eastern
Extended Trading
$1.13 +0.00 (+0.09%)
As of 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Finch Therapeutics Group stock logo

Finch Therapeutics Group NASDAQ:FNCH

$12.50 -0.25 (-1.96%)
As of 02:15 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Fresh Tracks Therapeutics stock logo

Fresh Tracks Therapeutics NASDAQ:FRTX

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.41 -0.02 (-0.58%)
Closing price 04:00 PM Eastern
Extended Trading
$3.40 -0.01 (-0.26%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.